The long-term tolerability of bencyclane ('Fludilat') in patients with peripheral occlusive disease: a 48-week prospective double-blind controlled study versus placebo.

@article{Herrmann1991TheLT,
  title={The long-term tolerability of bencyclane ('Fludilat') in patients with peripheral occlusive disease: a 48-week prospective double-blind controlled study versus placebo.},
  author={W. Herrmann and E. Sch{\"a}rer},
  journal={Current medical research and opinion},
  year={1991},
  volume={12 6},
  pages={
          356-65
        }
}
In a controlled, multi-centre, double-blind trial, 75 patients with Stage II peripheral occlusive disease (Fontaine IIa) were treated with either 200 mg bencyclane twice daily or placebo over a period of 12 months. Undesired drug effects and concomitant phenomena were documented, and efficacy was evaluated. Bencyclane caused a slight, clinically negligible decrease in blood pressure. The pulse rate remained mostly unchanged, ECG and laboratory parameters showed no changes which would indicate a… Expand
Matched-pair study showed higher quality of placebo-controlled trials in Western phytotherapy than conventional medicine.
TLDR
The findings challenge the widely held belief that the quality of the evidence on the effectiveness of herbal medicine is generally inferior to the evidence available for conventional medicine. Expand
Effect of vasoactive drugs on antioxidant status and endothelial function in patients with chronic lower limb ischaemia in Fontaine’s stage IIb
TLDR
U wszystkich pacjentow przeprowadzono: badanie dystansu przejścia do pierwszego bolu (PFWD), maksymalnego (MWD) i zmierzono wskaźnik kostka-ramie (ABI). Expand

References

SHOWING 1-4 OF 4 REFERENCES
Study of platelet aggregation in vivo i. Effect of bencyclan.
A 20mu diameter pore size screen was inserted into an arterio-venous bypass system in heparinized stumptailed monkeys. ADP and serotonin injection resulted in aggregation of platelets on the screenExpand